Start: March 2, 2020
End: March 1, 2024
What Is This Study About?
This study will test the effects of repetitive transcranial magnetic stimulation (rTMS), a noninvasive brain stimulation therapy, on cognitively healthy older adults and in people with amnestic mild cognitive impairment due to Alzheimer's disease. The intervention is designed to improve cognition, including memory, in older adults. All study participants will receive the rTMS intervention followed by a functional connectivity MRI to determine any changes in the brain. Participants will also undergo neuropsychological and memory testing to determine improvements in cognition.
Do I Qualify To Participate in This Study?
- Fluent English speaker
- Willing and able to consent to the study directions and undergo imaging and neuropsychological testing at the specified time points
- Patients with very mild or mild cognitive impairment (CDR 0.5 or CDR 1)
- Participants with amnestic mild cognitive impairment must be able to bring a study partner to all visits
Must NOT have:
- History of head trauma involving a loss of consciousness or alteration in consciousness
- Physician diagnosis of another major neurologic or psychiatric condition
- Known presence of a structural brain lesion (e.g., tumor, cortical infarct)
- Any condition that makes imaging by MRI unsafe, such as the presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body
- Longstanding history (i.e., longer than 10 years) of alcohol or substance abuse
- Any significant illness or unstable medical condition that could make it difficult to comply with the study directions
- Unable or unwilling to return for follow-up, undergo neuropsychological testing, transcranial magnetic stimulation, and MRI imaging
If I Qualify, Who Do I Contact?
Contact study personnel listed either under the general study contact or the location nearest you.
Jessica A Collins, PhD
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Where Is This Study Located?
Lead: Massachusetts General Hospital
Source: ClinicalTrials.gov ID: NCT04294888